BEYOND_3A | R Documentation |
Kaplan-Meier digitized data from BEYOND, figure 3A (PMID 26014294). A reported sample size of 276 for a primary endpoint of PFS in prostate cancer.
BEYOND_3A
A data frame of 276 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (bev_cp, placebo_cp) | |
Zhou C, Wu Y-L, Chen G, et al. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2197–204.
summary(BEYOND_3A)
kmplot(BEYOND_3A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.